quinolinic acid has been researched along with roflumilast in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhat, A; Chidambaram, SB; Essa, MM; Guillemin, GJ; Heng, B; Lovejoy, DB; Sakharkar, MK; Tan, V | 1 |
| Akhtar, A; Bansal, Y; Bishnoi, M; Kuhad, A; Sah, SP; Saroj, P; Singh, R; Sodhi, RK | 1 |
2 other study(ies) available for quinolinic acid and roflumilast
| Article | Year |
|---|---|
Roflumilast, a cAMP-Specific Phosphodiesterase-4 Inhibitor, Reduces Oxidative Stress and Improves Synapse Functions in Human Cortical Neurons Exposed to the Excitotoxin Quinolinic Acid.
Topics: Aminopyridines; Benzamides; Brain-Derived Neurotrophic Factor; Cyclic AMP Response Element-Binding Protein; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Humans; Neurons; Neurotoxins; Oxidative Stress; Phosphodiesterase 4 Inhibitors; Quinolinic Acid; Synapses | 2020 |
Neuroprotective effects of roflumilast against quinolinic acid-induced rat model of Huntington's disease through inhibition of NF-κB mediated neuroinflammatory markers and activation of cAMP/CREB/BDNF signaling pathway.
Topics: Aminopyridines; Animals; Benzamides; Brain-Derived Neurotrophic Factor; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Huntington Disease; Inflammation; Male; Neuroprotective Agents; NF-kappa B; Nitrosative Stress; Oxidative Stress; Quinolinic Acid; Rats; Rats, Wistar; Signal Transduction | 2021 |